Clinical Research Directory
Browse clinical research sites, groups, and studies.
Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation
Sponsor: Jasper A. Smits
Summary
The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2020-01-22
Completion Date
2023-06-14
Last Updated
2026-06-15
Healthy Volunteers
Yes
Conditions
Interventions
Isradipine
Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
Cue Exposure
Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
Locations (1)
University of Texas at Austin
Austin, Texas, United States